Last reviewed · How we verify
Clinolipid
At a glance
| Generic name | Clinolipid |
|---|---|
| Sponsor | Baxter Healthcare Corporation |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
- Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients (PHASE4)
- Personalized Nutrition to Improve Recovery in Trauma (PHASE2)
- LIPIDS-P Trial Phase I/II Trial (PHASE1, PHASE2)
- Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A) (PHASE4)
- Impact of IDPN on Nutrition Markers in Patients Receiving ICHD
- Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants (PHASE3)
- Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clinolipid CI brief — competitive landscape report
- Clinolipid updates RSS · CI watch RSS
- Baxter Healthcare Corporation portfolio CI